Summary-Defects in ion channel activity have been linked to increased susceptibility to cardiac arrhythmia in congenital and acquired forms of heart disease. Over the past 20 years, gene variants in ion channels have been discovered that increase arrhythmia susceptibility by altering ion channel biophysics. Although these studies have generated insight into molecular mechanisms underlying human disease and have advanced our understanding of ion channel function, the mechanistic link between specific molecular defects and arrhythmias remains elusive in many cases. Membrane protein posttranslational modifications are an essential mechanism for regulating cell function in heart. Importantly, alterations in posttranslational modification of ion channel proteins have now been identified in heart disease. Our findings demonstrate that human variants that modify a validated phosphorylation motif for Ca2+/calmodulindependent kinase in the cardiac sodium channel confer a proarrhythmic cellular phenotype by mimicking the Ca2+/calmodulin-dependent protein kinase II-phosphorylated channel. Moreover, we provide data that a similar defect in posttranslational modification of Nav1.5 is present in a large-animal model of ischemic heart disease and human heart failure. We propose that the A572D and Q573E human arrhythmia variants belong to an emerging class of atypical ion channel mutations that confer arrhythmia susceptibility by affecting posttranslational modification. These studies add to mounting evidence that defects in local signaling and protein posttranslational modification help define disease phenotypes associated with a broad range of cardiac arrhythmia syndromes.
Conclusions-We identify the mechanism for 2 human arrhythmia variants that affect Nav1.5 channel activity through direct effects on channel posttranslational modification. We propose that the CaMKII phosphorylation motif in the Nav1.5 DI-DII cytoplasmic loop is a critical nodal point for proarrhythmic changes to Nav1.5 in congenital and acquired cardiac disease. 1
Modeling Supravalvular Aortic Stenosis Syndrome With Human Induced Pluripotent Stem Cells
Summary-Currently, treatment of proliferation-based pathologies relies on drugs like rapamycin that may have a broad impact on patient physiology. Such treatment risks unintended effects in targeted and off-target cell types, potentially initiating new dysfunction. To effectively treat patients, it is critical to root out the mechanisms of proliferative diseases so that treatments can be developed to specifically attack the existing pathology without risking further complication. This study shows for the first time that the hyperproliferation in smooth muscle cells (SMCs) that causes supravalvular aortic stenosis (SVAS) syndrome is, in turn, accompanied by a marked decrease in actin filament bundle formation and an increase in migration. More important, we have shown that treatment with exogenous elastin monomers rescues the actin filament bundle formation in supravalvular aortic stenosis cells. With these results taken together, it can be hypothesized that a switch from a contractile to a proliferative phenotype in smooth muscle cells is caused by an elastin deficiency. Induced, pluripotent stem cell models of proliferative diseases such as the one used here should prove valuable in the search for candidate pathways and pharmaceutical agents. As a result, clinical interventions focusing on the enhancement of smooth muscle cell actin filament bundle formation and/or elastin production of affected vessel walls promise higher efficacy and lower risk to the patient than current treatments. There are several avenues through which such interventions can be realized, but given a candidate drug specific to actin filament bundle formation and/ or elastin production, the goal of curing deadly proliferation-based smooth muscle cell diseases appears to be close at hand.
Conclusions-SVAS iPSC-SMCs recapitulate key pathological features of patients with SVAS and may provide a promising strategy to study disease mechanisms and to develop novel therapies. 2 a heritable disorder characterized by both laterality defects and also sinopulmonary disease arising from airway cilia motility defects that compromise mucus clearance. Using 2 simple tests normally used for PCD assessment, we showed that 42% of heterotaxy patients with CHD have airway ciliary dysfunction (CD). This included the observation of abnormal cilia motility by videomicroscopy of nasal scrapes, and also low nasal nitric oxide (NO) levels similar to the low NO levels seen with PCD. Furthermore, sequencing analysis showed that heterotaxy patients with CD are significantly enriched for novel coding variants in genes known to cause PCD. Together these findings suggest that CHD patients with heterotaxy may benefit from preoperative screening for CD, with pulmonary therapy to be provided prophylactically to enhance airway clearance in patients with CD. Such a change in the standard of care may improve outcome and reduce morbidity/mortality in CHD patients with heterotaxy.
Conclusions-Our studies show that CHD patients with heterotaxy have substantial risk for CD and increased respiratory disease. Heterotaxy patients with CD were enriched for mutations in PCD genes. Future studies are needed to assess the potential benefit of prescreening and prophylactically treating heterotaxy patients for CD. 3 
Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events: Implications for Mutation-Specific Response to β-Blocker Therapy in Type 1 Long-QT Syndrome
Summary-Long-QT syndrome type 1 (LQT1) arises from a decrease in repolarizing potassium current resulting from mutations in the KCNQ1 gene. The main trigger for cardiac arrhythmic events in patients with LQT1 is activation of β1-adrenergic receptors during exercise. Despite the observed reduction in the risk of cardiac events with β-blocker therapy among LQT1 patients, there is still a considerable cardiac residual event rate, suggesting that subgroups of LQT1 patients have differential response to β-blockers. The present study of 860 patients from the International LQTS Registry shows that the presence of missense mutations in distinct functional domains of the KCNQ1 protein, the S2-S3 and S4-S5 cytoplasmic loops (C loops), is associated with a significantly increased risk for life-threatening cardiac events compared with other mutations. Furthermore, patients with missense C-loop mutations gained greater benefit when treated with β-blockers compared with patients having other KCNQ1 mutations independently of clinical risk factors, demonstrating that LQT1 patients have differential response to β-blocker therapy depending on mutation location. Both a decrease in basal function and altered adrenergic regulation of the IKs channel underlie the increased cardiac risk and response to β-blockers in this subgroup of patients. Patients with missense C-loop mutations should be considered a high-risk group of patients but with a pronounced response to β-blockers.
Conclusions-Patients with C-loop missense mutations in the KCNQ1
channel exhibit a high risk for life-threatening events and derive a pronounced benefit from treatment with β-blockers. Reduced channel activation after sympathetic activation can explain the increased clinical risk and response to therapy in patients with C-loop mutations. 4
A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)
Summary-Warfarin is characterized by marked variations in individual dose requirements and a narrow therapeutic window. Much of this variability is explained by common reduced-function variants in 2 genes, CYP2C9 and VKORC1. Pharmacogenetic (PG) guidance of warfarin initiation could improve dosing efficiency and safety, but evidence from clinical trials is still meager. To increase understanding of the potential role of PG guidance in warfarin dose initiation and to build on an earlier study (CoumaGen-I), we designed a second 3-month study (CoumaGen-II) with 2 parts: (1) a blinded, randomized comparison of a modified 1-step (PG-1) with a 3-step PG algorithm (PG-2) (N=504) and (2) a clinical effectiveness comparison of PG-guided with standard dosing in a parallel (nonrandomized) control group (N=1866) within the Intermountain Healthcare system. A rapid method provided same-day CYP2C9 and VKORC1 genotyping. In the randomized comparison, PG-2 was noninferior but not superior to PG-1 for the primary end point of percentage of out-of-range international normalized ratios at 1 month and at 3 months and for percentage of time in therapeutic range at 3 months, suggesting that the simpler 1-step PG algorithm may be preferable for clinical application. However, PG guidance (combined cohort) was substantially superior to standard dosing in the parallel control group for these end points (all P<0.001). PG guidance also reduced percentage of international normalized ratios ≥4 and ≤1.5 and serious adverse events. These clinical effectiveness findings suggest that PG dosing should be considered for broader clinical application, a proposal that is being tested further in 3 major randomized trials. The simpler 1-stage PG algorithm provided equivalent results and may be preferable for clinical application.
Conclusions-These findings suggest that PG dosing should be considered for broader clinical application, a proposal that is being tested further in 3 major randomized trials. The simpler 1-step PG algorithm provided equivalent results and may be preferable for clinical application. 5
Genome-Wide Association Study for Coronary Artery Calcification With Follow-Up in Myocardial Infarction
Summary-Coronary artery calcification, detected by computed tomography, is a noninvasive measure of coronary atherosclerosis and an independent predictor of myocardial infarction. We conducted a genome-wide association study with a discovery sample of nearly 10 000 participants of European original and a replication sample of >6000 participants of European origin. We report strong evidence for genetic variants in 9p21 near the CDKN2B and CDKN2A genes and in 6p24 within the PHACTR1 gene. Additionally, we found evidence for concordance of single-nucleotide polymorphism associations with both coronary artery calcification and some but not all other loci known to be associated with myocardial infarction, including 3q22 (MRAS gene), 13q34 (COL4A1/COL4A2 genes), and 1p13 (SORT1 gene). These findings reinforce the important role of variation at multiple genes in the pathogenesis of coronary atherosclerosis. Although the functional mechanism of many of these genetic associations remains to be determined, our comprehensive study lays the groundwork for future studies to determine the role of several genes in treatment, prediction, and prevention of coronary atherosclerosis and resulting myocardial infarction and other clinically apparent forms of coronary heart disease.
Conclusions-SNPs in the 9p21 and PHACTR1 gene loci were strongly associated with coronary artery calcification and myocardial infarction, and there are suggestive associations with both coronary artery calcification and myocardial infarction of SNPs in additional loci. Multiple genetic loci are associated with development of both underlying coronary atherosclerosis and clinical events. 6
Distinct Epigenomic Features in End-Stage Failing Human Hearts
Summary-Molecular research in heart failure points to the hypothesis that a generic cardiac genomic response is activated in the failing myocardium regardless of the original inciting cause. This cardiac genomic stress response is typified by the re-expression of fetal genes, upregulation of fibrosis-related genes, and others. It may also reflect unifying features of a failed myocardium such as fibrosis, altered energy use, vascular rarefaction, cell death, and altered contractility, all of which are features found in the failing myocardium again regardless of the inciting cause. The epigenome refers to "marks" on the genome, including DNA methylation and histone modification. The epigenome regulates the expression of underlying genes, and recent evidence suggests that part of the epigenome may be altered by diet and the environment. In our research, we have examined the genome-wide landscape of the epigenome of healthy and end-stage cardiomyopathic human hearts. We have determined that distinct epigenomic patterns exist in important DNA elements of the human cardiac genome in the failing myocardium. Individually, sites of differential epigenomic patterns may control the expression of specific genes with critical functions in the progression of heart failure. However whether the altered epigenome is simply a consequence in end-stage disease or actually contributes to disease progression remains to be determined. This work now opens an important new avenue of research because the epigenome may represent a drug discovery target for novel heart failure therapy.
Conclusions-Distinct epigenomic patterns exist in important DNA elements of the cardiac genome in human end-stage cardiomyopathy. The epigenome may control the expression of local or distal genes with critical functions in myocardial stress response. If epigenomic patterns track with disease progression, assays for the epigenome may be useful for assessing prognosis in heart failure. Further studies are needed to determine whether and how the epigenome contributes to the development of cardiomyopathy. 7
Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy: Pathogenic Desmosome Mutations in Index-Patients Predict Outcome of Family Screening: Dutch Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Genotype-Phenotype Follow-Up Study
Summary-Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) usually shows an autosomal dominant inheritance pattern, with incomplete penetrance and variable clinical expression. Classically, index patients present between the second and fourth decades of life with right ventricular tachycardia. However, sudden death can occur at adolescence, whereas mutation carriers may remain without signs and symptoms until old age. Previous genotype-phenotype studies involved mainly overt index patients. Data on mainly asymptomatic relatives were scarce. To gain insight into the full spectrum of the disease, 149 ARVD/C index patients and 302 of their relatives were genotypically and phenotypically characterized. DNA analysis comprised sequencing of the desmosomal genes PKP2, DSC2, DSG2, DSP, and JUP and multiplex ligation-dependent probe amplification to identify large deletions in PKP2. Pathogenic mutations were identified in 87 of 149 ARVD/C index patients (58%), mainly truncating PKP2 mutations with multiple mutations in 2% of cases. Performing multiplex ligation-dependent probe amplification also appeared to be important; its 2% mutational yield was comparable to the sequencing of DSG2 or DSC2. Identification of mutations in index patients had major consequences for the concurrent relatives.
Of the 57 of 282 initially asymptomatic relatives (20%) who showed any sign of ARVD/C, 84% carried a mutation. These 48 mutation carriers had earlier onset of disease signs and symptoms than noncarriers but also a markedly increased risk of arrhythmias and 6-fold risk of ARVD/C diagnosis. Familial cases were identified in 45% of families screened. Prolonged terminal activation duration seemed to be an early marker of ARVD/C; it was observed more often than negative T waves in V1 to V3, especially in mutation-carrying relatives <20 years of age.
Conclusions-Pathogenic desmosomal gene mutations, mainly truncating PKP2 mutations, underlie ARVD/C in the majority (58%) of Dutch index patients and even 90% of familial cases. Additional multiplex ligation-dependent probe amplification analysis contributed to discovering pathogenic mutations underlying ARVD/C. Discovering pathogenic mutations in index patients enables those relatives who have a 6-fold increased risk of ARVD/C diagnosis to be identified. Prolonged terminal activation duration seems to be a first sign of ARVD/C in young asymptomatic relatives. 8
Cardiac Structural and Sarcomere Genes Associated With Cardiomyopathy Exhibit Marked Intolerance of Genetic Variation
Summary-Recent studies have revealed a high degree of genetic variation in human populations, some of which would be predicted to cause loss of function of the genes encoded. These studies provide a challenge to the careful interpretation of the results from genetic testing and raise concerns about our ability to distinguish between benign and pathogenic variants. We analyzed data from >5000 participants in the National Heart, Lung, and Blood Institute Exome Sequencing Project. To study tolerance of genetic variation in different genes, we derived rates of genetic variation within (1) genes without Mendelian disease association, (2) genes associated with Mendelian disease, and (3) genes associated with inherited cardiomyopathies. We found that genes associated with Mendelian diseases exhibit markedly lower rates of genetic variation. This was even more marked for genes associated with cardiomyopathy. Nonsense variants were extremely rare in most cardiomyopathy genes, suggesting that when such variants are found, they are likely to be pathogenic. We also compared known pathogenic variants in MYH7, MYBPC3, and TNNT2 with those in the population data. We found neither rarity nor nucleotide evolutionary conservation helpful in distinguishing benign from pathogenic variants in these genes. However, the exon distribution of pathogenic and benign variants in MYH7 and TNNT2 was significantly different. Rates of pathogenic variants in population data were higher than would be anticipated, suggesting that a single gene/variant model may not be sufficient to explain many cases of inherited cardiomyopathy. These findings highlight the continued importance of cosegregation and other supporting data in determining variant pathogenicity.
Conclusions-Genes associated with cardiomyopathy carry very low rates of population variation. The existence in population data of variants with strong evidence for pathogenicity suggests that even for Mendelian disease genetics, a probabilistic weighting of multiple variants may be preferred over the single gene causality model. 9
TGFβRIIb Mutations Trigger Aortic Aneurysm Pathogenesis by Altering Transforming Growth Factor β2 Signal Transduction
Summary-Thoracic aortic aneurysm (TAA) is a common progressive disorder involving gradual dilation of the ascending and/or descending thoracic aorta that is clinically unsuspected until potentially lethal aortic dissection or rupture. TAA is often part of a complex connective tissue syndrome such as Marfan, Loeys-Dietz, and Ehlers-Danlos syndromes, but nonsyndromic TAAs also occur as genetically triggered inherited disorders. Genetically triggered TAAs account for ≈20% of TAAs. Prior analyses of familial TAA in research cohorts have identified disease-causing mutations in genes encoding myosin heavy chain 11 (MYH11), α-smooth muscle actin (ACTA2), and transforming growth β receptors I and II (TGFβRI and TGFβRII). Mutational analyses of these 4 genes were now performed in a cohort of patients routinely presenting to cardiovascular clinics and suspected to have genetically mediated nonsyndromic aortic disease. Nine percent of patients had a mutation in one of the 4 genes analyzed. Three percent of patients had mutations in ACTA2, 3% in MYH11, and 3% in TGFβRII. TGFβRII mutations included ones identified in an alternatively spliced TGFβRII exon, exon 1a, that encodes the TGFβRIIb isoform. These TGFβRII exon 1a mutations occurred in 2% of these TAA patients and suggest that altered TGFβ2 signaling contributes to aneurysm pathogenesis. This study's findings support the potential value to cardiovascular practitioners of genetic testing with a multigene aortic disease gene panel in the diagnostic workup of TAA patients.
Conclusions-We propose that TGFβRIIb expression is a regulatory mechanism for TGFβ2 signal transduction. Dysregulation of the TGFβ2 signaling pathway, as a consequence of TGFβRIIb mutations, results in aortic aneurysm pathogenesis. 10
Impact of Ancestry and Common Genetic Variants on QT Interval in African Americans
Summary-Ethnic differences in cardiac arrhythmia incidence have been reported, with a particularly high incidence of ventricular fibrillation and sudden cardiac death and a low incidence of atrial fibrillation in African Americans compared with Americans of European ancestry. However, it remains unknown whether such differences result from differences in inherited myocardial electrophysiological properties. Previous studies have shown inconsistent results regarding ethnic differences in electrocardiographic QT interval, a measure of myocardial repolarization time, and a central pathophysiological determinant of arrhythmia known to have a strong genetic component. In the present study, we therefore studied whether African compared with European ancestry inferred from genome-wide genotype data were associated with QT interval in 12 000 African Americans from 7 population-based studies. We observed no difference in duration of QT interval with African compared with European ancestry, arguing against important differences in myocardial repolarization time across these ethnicities. We also performed a genome-wide association study to identify common genetic variants associated with electrocardiographic QT interval in 13 000 blacks from 10 cohorts and observed association with QT interval for several loci previously identified as genetic determinants of QT interval in individuals of European ancestry, including SNPs at genetic loci harboring the genes NOS1AP, ATP1B1, KCNQ1, KCNH2, LITAF, and PLN.
Conclusions-We observed no difference in duration of cardiac repolarization with global genetic indices of African American ancestry. In addition, our genome-wide association study extends the association of polymorphisms at several loci associated with repolarization in individuals of European ancestry to include individuals of African ancestry. 11
Identification of the BCAR1-CFDP1-TMEM170A Locus as a Determinant of Carotid Intima-Media Thickness and Coronary Artery Disease Risk
Summary-Carotid intima-media thickness, determined by highresolution ultrasound techniques, is a well-established marker of subclinical atherosclerosis that has been shown to predict incident coronary and cerebrovascular events and is frequently used in both academic research and clinical trials. Genetic association studies of carotid intima-media thickness in individuals free of manifest cardiovascular disease may identify genes involved in early phases of disease, which may be less readily discernible in studies of late-stage disease. In the present study, we performed a genetic association analysis of carotid intima-media thickness in 3430 participants of the pan-European population-based IMPROVE study, who have undergone uniquely extensive ultrasound examinations of the carotid tree. We used a custom genotyping array (the Illumina CardioMetabochip), which interrogates genomic regions identified by previous genomewide association studies of metabolic and cardiovascular disease. In the second stage, we conducted replication studies and subsequently tested 1 locus for association with coronary artery disease risk and with mRNA expression of nearby genes in vascular tissue biobanks. We thus identified a locus on chromosome 16, containing the BCAR1, CFDP1, and TMEM170A genes, as a novel genetic determinant of carotid intima-media thickness and coronary artery disease risk. Of these genes, BCAR1 has the most plausible role in atherogenesis based on current literature, whereas TMEM170A, which was highlighted by the biobank expression analysis, is an intriguing lead because its biological function is not known. Thus, this study has identified a novel genetic locus of importance for atherosclerosisrelated disease, indicating specific genes that merit further research, results of which may become of future clinical use.
Conclusions-This study identified rs4888378 in the BCAR1-CFDP1-TMEM170A locus as a novel genetic determinant of carotid intima -media thickness and coronary artery disease risk in individuals of European descent. 12
Low Prevalence of Mutations in Known Loci for Autosomal Dominant Hypercholesterolemia in a Multiethnic Patient Cohort
Summary-Patients with autosomal dominant hypercholesterolemia (ADH) present with very high low-density lipoprotein-cholesterol levels accompanied by tendon xanthomas and premature coronary heart disease. Worldwide, several countries have undertaken systematic screening efforts to identify patients with mutations in the genes known to cause ADH, and disease-causing mutations have been found in up to 95% of ADH patients. However, most of these screening studies have been performed in Europe or in Japan and are from relatively homogenous populations with regard to ethnicity and race. As a result, there is a paucity of data in subjects of African origin and other minorities. Therefore, we examined the molecular basis of ADH in a multiethnic patient cohort from a large, urban US city (Dallas, TX). We identified 91 unrelated ADH patients and screened them for mutations in the known genes: low-density lipoproteincholesterol receptor, apolipoprotein B-100, and proprotein convertase subtilisin-like kexin type 9. Sixty ADH patients did not have mutations in any of these genes (unexplained ADH). A higher proportion of blacks (77%) than either non-Hispanic whites (57%) or Hispanics (53%) had unexplained ADH. Compared with patients with lowdensity lipoprotein receptor variants, those with unexplained ADH had lower levels of low-density lipoprotein-cholesterol (292±47 mg/ dL versus 239±42 mg/dL, respectively; P<0.0001) and higher levels of high-density lipoprotein-cholesterol (45±12 mg/dL versus 54±13 mg/dL, respectively, P=0.003). Our findings suggest that additional loci may contribute to ADH, especially in understudied populations such as blacks.
Conclusions-Our findings suggest that additional loci may contribute to ADH, especially in understudied populations such as blacks. 13
Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives: Results From the Pharmacogenomic Evaluation of Antihypertensive Responses Study
Summary-Hypertension is the most common chronic disease for which medications are prescribed, and controlling blood pressure (BP) is important in reducing long-term mortality and morbidity. Response rates to monotherapy with any given antihypertensive drug are only ≈50%, and those who fail to response to 1 drug class are more likely to respond to a drug with an alternate mechanism. Current selection of initial antihypertensive therapy is essentially by trial and error. The difficulty in determining the most appropriate antihypertensive drug for a specific patient likely contributes to the fact that less than half of the hypertensive patients in the United States (and worldwide) currently have their BP controlled. Pharmacogenomics offers the clinical promise of individualization of therapy based on a person's genetic makeup. Through genome-wide association studies, 39 genetic polymorphisms have been associated with BP or hypertension in white individuals to date. However, whether these genetic markers are also associated with BP response to commonly used antihypertensives is unclear. In this study, we assessed the association of these genetic markers with BP responses after 9 weeks of monotherapy in white patients with essential hypertension who were randomized to a β-blocker (atenolol) or a thiazide diuretic (hydrochlorothiazide) in a randomized clinical trial. Six of these markers were nominally associated with BP response to either atenolol or hydrochlorothiazide when evaluated individually. However, these markers were much more strongly associated with the BP response to the antihypertensives when considered collectively. These findings suggest that selected signals from hypertension genome-wide association studies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring.
Conclusions-These findings suggest that selected signals from hypertension genome-wide association studies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring. 14
Spongious Hypertrophic Cardiomyopathy in Patients With Mutations in the Fourand-a-Half LIM Domain 1 Gene
Summary-Male patients with X-linked myopathy caused by mutations in the C terminus of the FHL1 gene show hypertrophic cardiomyopathy with midventricular and apical hypertrophy, replacement fibrosis, and spongious structure. This unique form of hypertrophic cardiomyopathy is reflected in electric and functional abnormalities that can be identified at an early stage of disease with strain and strain rate imaging. An unexpected finding was that some cardiac abnormalities were also present in heterozygous female mutation carriers. We propose that all mutation carriers should undergo cardiological screening as early as possible, as the cardiological phenotype becomes apparent before neurological signs of disease can be diagnosed. Systematic cardiac phenotyping of patients and family members with mutations in FHL1 may allow better risk stratification and earlier initiation of management strategies.
Conclusions-X-linked myopathy with postural muscle atrophy patients consistently showed electric, functional, and characteristic morphological cardiac abnormalities that translate into reduced exercise capacity. Reduced systolic and diastolic function is associated with a novel type of spongious hypertrophic cardiomyopathy. An unexpected finding was that some cardiac abnormalities were also present in heterozygous female mutation carriers. 15
Subtle Abnormalities in Contractile Function Are an Early Manifestation of Sarcomere Mutations in Dilated Cardiomyopathy
Summary-Sarcomere gene mutations play an important role in genetic cardiomyopathies. They are present in a prominent subset of patients with dilated cardiomyopathy (DCM) and in the majority of patients with familial hypertrophic cardiomyopathy (HCM). However, the precise mechanistic steps that lead from mutation to clinically obvious disease are not well understood. Sarcomere mutation carriers typically do not manifest disease at birth. A subclinical phase may last for decades, even indefinitely, before overt cardiomyopathy develops. This implies that sarcomere mutations can be well-tolerated and that disease-modifying treatments could potentially be developed to prolong the compensated state or prevent disease development entirely. The finding that both HCM and DCM can be caused by different mutations in the same sarcomeric proteins highlights the complex interplay between genotype and phenotype. Experimental models have demonstrated that the intrinsic biochemical and mechanical properties of mutations that give rise to DCM are different from mutations that give rise to HCM. In this study we begin to characterize the early consequences of DCM sarcomere mutations and contrast them to mutations associated with HCM in a human population. Tissue Doppler and strain echocardiography suggest that subtle systolic dysfunction is present in subclinical DCM mutation carriers, despite normal left ventricular dimensions and ejection fraction. In contrast, diastolic function appeared to be preserved. These findings are opposite those seen in subclinical HCM sarcomere mutation carriers where preserved systolic function and impaired diastolic function have been described. These differences may play a critical role in shaping downstream cardiac remodeling.
Conclusions-Subtle abnormalities in systolic function are present in subclinical DCM mutation carriers, despite normal left ventricular size and ejection fraction. In contrast, impaired relaxation and preserved systolic function appear to be the predominant early manifestations of sarcomere mutations that lead to HCM. These findings support the theory that the mutation's intrinsic impact on sarcomere function influences whether a dilated or hypertrophic phenotype develops. 16
BMPR2 Mutations Influence Phenotype More Obviously in Male Patients With Pulmonary Arterial Hypertension
Summary-BMPR2 mutations are major predisposing factors for idiopathic and heritable pulmonary arterial hypertension (IPAH and HPAH). The influence of BMPR2 mutations on clinical outcomes has been reported, but the data are not concordant in different ethnic groups. The current study sought to identify the association of BMPR2 genotypes on clinical outcomes, and whether any potential association varies by sex in a large group of Chinese IPAH and HPAH patients who underwent genetic counseling in Shanghai Pulmonary Hospital. We compared clinical, functional, and hemodynamic characteristics of BMPR2 mutation carriers and noncarriers. Our data indicate that BMPR2 mutation carriers present with a severe phenotype of PAH, with more severe hemodynamic compromise, an earlier age at death, and poor overall survival. BMPR2 mutations influence outcomes more in male PAH patients, which was reflected by a higher mortality risk of male mutation carriers than that of male noncarriers after adjustment for age at diagnosis (hazard ratio, 3.702; 95% confidence interval, 1.416-9.679; P=0.008). Considering the female predominance in PAH, the pathogenesis of PAH in women is likely more complicated and the influence of BMPR2 mutations may be modified by other unknown factors, making disparities in the prognosis between female BMPR2 mutation carriers and noncarriers less evident. The current study underscores the unique characteristics in PAH patients of Chinese origin. The genetic and epidemiological characteristics of the Chinese Han population may be unique and distinct from those of non-Han (or Western) populations. Thus, comparisons between Han and non-Han patients with PAH may yield insights into the causes in each of these populations.
Conclusions-BMPR2 mutations influence phenotype more obviously in male PAH patients. The pathogenesis of female PAH patients is more complicated, and the influence of BMPR2 mutations may be modified by other unknown factors, making disparities in the prognosis between female mutation carriers and noncarriers less evident. 17
Population-Based Variation in Cardiomyopathy Genes
Summary-The 1000 Genomes Project is an international consortium designed to provide full genomic sequence information from an ethnically varied population. The clinical history of 1000 Genomes Project participants is unknown, so information from the project is best used to determine population estimates of sequence variation. We queried the 1000 Genomes Project database for genetic variation in three cardiomyopathy genes, MYH7 (β myosin heavy chain), MYBPC3 (myosin binding protein C), and TTN (titin). We focused our analysis on rare variation that was either reported previously as pathogenic or was predicted to be pathogenic by computational algorithms. These 3 genes encode sarcomere proteins, and mutations in these genes cause familial dilated and hypertrophic cardiomyopathy. We identified predicted and previously reported pathogenic variation at a much higher frequency than the incidence of both dilated and hypertrophic cardiomyopathy. Specifically, we found 9% of genomes had insertion/deletion polymorphisms in TTN. The functionality of this genetic variation is not known given the absence of clinical information from 1000 Genomes Project participants; however, these variants may be important genetic modifiers that increase the risk for developing heart failure in the general population. For patients with a history of familial cardiomyopathy, these findings favor comprehensive genetic testing to identify both primary mutations and secondary disease modifiers.
Conclusions-Cardiomyopathy is a genetically heterogeneous disorder caused by mutations in multiple genes. The frequency of predicted pathogenic protein-altering variation in cardiomyopathy genes suggests that many of these variants may be insufficient to cause disease on their own but may modify phenotype in a genetically susceptible host. This is suggested by the high prevalence of TTN insertion/ deletions in the 1000 Genomes Project cohort. Given the possibility of additional genetic variants that modify the phenotype of a primary driver mutation, broad-based genetic testing should be used. 18
Molecular Insights into Arrhythmogenic Right Ventricular Cardiomyopathy Caused by Plakophilin-2 Missense Mutations
Summary-Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a primary cardiomyopathy with a genetic etiology and autosomal dominant inheritance, with incomplete penetrance that occurs most often. The disease is characterized clinically by a high incidence of ventricular arrhythmias and sudden cardiac death, and pathologically by degeneration of myocytes with replacement of fibro-fatty tissue. About half of the clinically diagnosed patients carry mutations in genes encoding components of the cardiac desmosome, including plakophilin-2 (PKP2), which is the most common disease gene for ARVC. Interestingly, the majority of PKP2 mutations are associated with translational frameshifts, leading to truncated proteins. However, there are also deleterious missense mutations that have been described to cause the disease. The present study focuses on genetic and molecular mechanisms of PKP2 missense and frameshift mutations, which we found lead in vitro to protein instability and degradation, suggesting haploinsufficiency as the main pathogenetic mechanism. Furthermore, we provide evidence that calpain proteases might be involved in the degradation of mutant proteins. We also established a cellular expression system to distinguish between variants of unknown significance (VUS) and pathogenic mutations; hereby selected VUS introduced into the PKP2 protein and expressed in vitro remain stable, whereas pathogenic mutations undergo protein degradation. This observation could be confirmed by bacterial expression experiments and structural modeling. Assuming a common mechanism of haploinsufficiency for all PKP2 mutations, cellular expression of mutant recombinant PKP2 proteins can provide further evidence for the pathogenicity of PKP2 mutations and might help in the decision process of variant classification in the future.
Conclusions-The p.C796R and other ARVC-related PKP2 mutations indicate loss of function effects by intrinsic instability and calpain proteases mediated degradation in in vitro model systems,
suggesting haploinsufficiency as the most likely cause for the genesis of dominant ARVC due to mutations in PKP2. 19 
A Common Variant in the PTPN11 Gene Contributes to the Risk of Tetralogy of Fallot
Summary-Known genetic syndromes such as Down and DiGeorge syndromes explain approximately 20% of cases of congenital heart disease. There remains a significant familial predisposition to congenital heart disease among the remaining ~80% of cases that are sporadic; 5% to 10% of these can be attributed to rare copy number variants in the genome, but other genetic risk factors remain largely unknown. No common genetic risk factors for congenital heart disease (defined as alleles with >5% frequency in the population) have as yet been robustly identified. We carried out a candidate-gene association study of tetralogy of Fallot (TOF), the most common cyanotic congenital heart disease phenotype. We found strong evidence of association between a common single nucleotide polymorphism in the PTPN11 gene (rs11066320) and TOF risk, which we replicated in a second independently ascertained cohort. Each copy of the risk allele increased the risk of TOF by ~30%. Sixtyfour percent of the population carries 1 or 2 copies of the risk allele. Rare gain-of-function mutations in the PTPN11 gene cause Noonan syndrome, which is a multisystem malformation syndrome in which pulmonary stenosis and TOF both occur. The long-range haplotype where the risk allele occurs, which spans PTPN11 and 14 other genes on chromosome 12q21, has been shown by others to be also associated with coronary artery disease, hypertension, blood platelet count, and a variety of autoimmune diseases. Although the relative risk of TOF conferred by rs11066320 alone is too small for genotype to be useful in risk profiling, larger studies incorporating genomewide data may discover additional loci. 
Conclusions-Common variation in the linkage

Prevalence of Sequence Variants in the RAS-Mitogen Activated Protein Kinase Signaling Pathway in Pre-Adolescent Children With Hypertrophic Cardiomyopathy
Summary-Hypertrophic cardiomyopathy (HCM) in children can be associated with malformation developmental syndromes, including Noonan syndrome (NS). NS and other related conditions are caused by mutations in genes encoding proteins of the RAS-mitogen activated protein kinase (MAPK) signaling pathway. Although diagnosis of these disorders is based on typical phenotypic features, the dysmorphic manifestations can be subtle and therefore overlooked. This study aimed to determine the prevalence of mutations in RAS-MAPK genes in 78 preadolescent children with apparently idiopathic HCM. Five probands (6.4%) carried novel sequence variants in 4 key genes of the RAS-MAPK pathway. Structural and molecular data suggest that these variants may have functional significance. Nine cardiac sarcomere protein genes were also screened; 2 individuals also had mutations in MYBPC. These findings suggest that genetic lesions promoting signaling dysregulation through RAS contribute to disease pathogenesis or progression in children with idiopathic and sarcomeric HCM. In particular, the results raise the possibility that some cases of HCM may represent incomplete phenotypic expression of RAS-MAPK disease. This has important implications for the evaluation and management of children with HCM, and further studies are needed to assess the possible interaction between sarcomere protein and RAS-MAPK genes.
Conclusions-This study reports novel and potentially pathogenic sequence variants in genes of the RAS-MAPK pathway, suggesting that genetic lesions promoting signaling dysregulation through RAS contribute to disease pathogenesis or progression in children with HCM. 21
Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension
Summary-Genetic causes of hereditary pulmonary arterial hypertension (HPAH) include bone morphogenetic protein receptor type 2, activin receptor-like kinase 1, endoglin, and mothers against decapentaplegic 9, but approximately 25% of HPAH cases lack identifiable mutations in any of these genes. We used whole exome sequencing to study a 3-generation family with multiple affected family members with PAH, but no identifiable mutation in the known HPAH genes, and identified a novel gene for HPAH: caveolin-1 (CAV1). We also identified a de novo frameshift mutation in a child with idiopathic PAH. CAV1 encodes a membrane protein of caveolae abundant in the endothelium and other cells of the lung. Caveolae are rich in cell surface receptors critical to initiation of a cellular signaling cascade, such as the transforming growth factor beta superfamily, nitric oxide pathway, and G-protein coupled receptors. Aberrant signaling at the plasma membrane may be the mechanism for PAH pathogenesis.
Our study demonstrates that mutations in CAV1 are associated in rare cases with familial and idiopathic PAH, and could provide new insight into the pathogenesis of PAH.
Conclusions-Our study represents successful elucidation of a dominant Mendelian disorder using whole exome sequencing. Mutations in CAV1 are associated in rare cases with PAH. This may have important implications for pulmonary vascular biology, as well as PAHdirected therapeutic development. 22
Discriminative Ability of LDL-Cholesterol to Identify Patients With Familial Hypercholesterolemia: A Cross-Sectional Study in 26 406 Individuals Tested for Genetic FH
Summary-Patients with familial hypercholesterolemia (FH) generally are at severely increased risk of coronary artery disease. Consequently, screening for FH within families is ongoing within several countries. Such screening is often based on cutoff values for lowdensity lipoprotein cholesterol. A potential limitation of this strategy is the overlap of these levels between carriers of an FH mutation and unaffected relatives. We studied the effect of selecting for severe mutations in a large Dutch cohort of 26 406 individuals, who underwent family screening for genetic FH. Our findings demonstrate that the separation of LDL-C levels between carriers and noncarriers was only modest for the entire cohort, as shown by an area under the curve (AUC) of 86.6% (95% CI, 85.9-87.2). The 90th percentile for LDL-C, for example, would label more than a quarter of patients with molecular FH as not having FH. In contrast, selection of subjects tested for the severe class 1 mutations in the LDLR did result in a marked separation of LDL-C levels between carriers and noncarriers, with a high AUC of 96.2% (95% CI, 95.3-97.1). Thus, regionspecific LDL-C cutoffs could work well for FH screening in other countries where primarily severe FH mutations are present. However, LDL-C specific cutoffs are of less clinical utility in our country, because of the high prevalence of LDL-receptor mutations of modest severity in the Netherlands.
Conclusions-In summary, the overlap in terms of LDL-C levels between those with molecularly proven FH and unaffected relatives is to a large extent because of the high prevalence of modestly severe LDL-receptor mutations in the Netherlands. 23
Cardiac Myosin Binding Protein-C Mutations in Families With Hypertrophic Cardiomyopathy: Disease Expression in Relation to Age, Gender, and Long Term Outcome
Summary-Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, and cardiac myosin binding protein C (MYBPC3) mutations are found in approximately 15% to 30% of probands. This study characterizes the phenotype of a large cohort of individuals with a MYBPC3 mutation. It suggests that powerful disease modifying factors influence the development and severity of disease, as disease expression is highly variable both between and within families sharing the same mutation. It also demonstrates reduced disease expression in female mutation carriers, suggesting the potential influence of hormonal, genetic, and environmental factors. Similar to previous studies, disease penetrance is incomplete throughout life; however, the development of the hypertrophic phenotype in adulthood is uncommon and the incidence of major disease related complications (such as stroke and sudden death) is similar to the rates seen in the HCM population as a whole. Finally, complex genetic status is common, which has implications for counseling family members and when considering predictive testing.
Conclusions-Disease expression in families with HCM related to MYBPC3 mutations shows marked heterogeneity with incomplete, agerelated, and gender specific penetrance. Importantly, complex genetic status is observed and should be considered when mutation analysis and cascade screening is used in the evaluation of at risk family members. 24
Evaluating Pathogenicity of Rare Variants From Dilated Cardiomyopathy in the Exome Era
Summary-Identification of the genetic cause of dilated cardiomyopathy is of great importance because the disease is clinically silent until late in its causal pathway. Early intervention can prevent or ameliorate the usual lethal and morbid presentation of the disease. Recent rapid advances in DNA sequencing technologies have made personalized medicine possible based on an individual's DNA sequence, but clinical impact will be determined by correct assessment of which genetic variants are pathogenic and which are benign. Dilated cardiomyopathy is a genetically heterogeneous disease, typically showing autosomal dominant transmission. Approximately 200 different variants in the DNA sequence across approximately 30 different genes are recorded in the literature, accounting for approximately 30% to 40% of disease causation. Eighty-eight percent of these variations (often described as "mutations") were considered "private" to individual families, that is, absent from the general population. However, older studies were limited by traditional sequencing cost to usually approximately 100 to 200 control DNAs. The Exome Sequencing Project (ESP), funded by the National Heart, Lung and Blood Institute, recently released a searchable public database containing genetic variants identified in thousands of individuals. Using the ESP data, this study collated DNA variants published as dilated cardiomyopathy causative and screened for their presence or absence within the ESP. Approximately 17% of genetic variants reported as causative of dilated cardiomyopathy were present in the ESP data. Detailed analysis suggested that some were falsepositives and some increased disease risk in the general population but had low penetrance. Variants at frequency >0.04% in the general population are of less certain pathogenicity, especially in sporadic cases.
Conclusions-Rare nonsynonymous variants identified in dilated cardiomyopathy subjects also present at very low frequencies in public databases are likely relevant for dilated cardiomyopathy. Allele frequencies >0.04% are of less certain pathogenicity, especially if identified in sporadic cases, although this cutoff should be viewed as preliminary. 25
Mortality of Inherited Arrhythmia Syndromes: Insight Into Their Natural History
Summary-For most arrhythmia syndromes, the risk of sudden cardiac death for asymptomatic mutation carriers is ill defined. Data on the natural history of these diseases are, therefore, essential for clinicians. The family tree mortality ratio method offers a unique opportunity to study the natural history at a time when the disease was not known and patients received no treatment (in large pedigrees tracing back many generations). In 6 inherited arrhythmia syndromes (3 long-QT syndrome subtypes, SCN5A overlap syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome) caused by specific mutations, we analyzed all-cause mortality with the family tree mortality ratio method, with the main outcome measure being the standardized mortality ratio. In all arrhythmia syndromes, excess mortality was observed in specific age categories. For these families, this information can be directly translated into clinical practice through guiding genetic and cardiovascular treatment and screening. For example, for the long-QT syndromes, excess mortality was observed in young age categories, particularly in type 1. We therefore advise starting genetic screening and cardiovascular screening of the first-degree family members at a very young age. In an SCN5A overlap syndrome family, excess mortality is from age 10 to 60 years (but starts to increase from age 5 years); therefore, implantation of a pacemaker may be postponed until well after age 5. For Brugada syndrome families, excess mortality was observed between age 40 and 59 years, especially in men. This finding warrants an expectant policy, particularly in asymptomatic female members in the first 3 decades of life.
Conclusions-We identified age ranges during which the mortality risk manifests in an unselected and untreated population, which can guide screening in these families. 26
Literature-Based Genetic Risk Scores for Coronary Heart Disease: The Cardiovascular Registry Maastricht (CAREMA) Prospective Cohort Study
Summary-Genome-wide association studies (GWAS) have identified many single-nucleotide polymorphisms (SNPs) associated with coronary heart disease (CHD) or its risk factors. We tested the combined effect of those SNPs on incident CHD in a Dutch population. By summing the number of risk alleles, 3 genetic risk scores (GRS) were constructed (ie, a GRS based on all 179 SNPs, 1 based on 153 risk factor-associated SNPs and 1 based on 29 CHD-associated SNPs). These GRS were associated with future CHD but not independent from traditional risk factors (ie, age, sex, smoking, self-reported diabetes, parental history of myocardial infarction, blood lipids, blood pressure, and body mass index). Next, a weighted CHD GRS was constructed by summing the number of CHD-associated risk alleles multiplied by their effect sizes obtained from 2 GWAS. This GRS was associated with CHD independent of traditional risk factors and improved risk reclassification. Effect sizes are sometimes difficult to obtain; therefore, as an exploratory analysis, least absolute shrinkage and selection operator (LASSO) regression analysis was used to obtain weighting. Using this method on the 29 CHD SNPs, 3 SNPs and corresponding weights were selected for a GRS. This GRS performed equally to the weighted CHD GRS. When applied on all 179 SNPs, 14 SNPs and corresponding weights were selected for a GRS, which performed slightly better than the weighted CHD GRS. Thus, weighting is important, and, when weights are not available, LASSO regression might be used to construct a weighted GRS; however, this method must be tested in independent populations.
Conclusions-A GRS composed of CHD SNPs improves risk prediction when adjusted for the effect sizes of the SNPs. Alternatively LASSO regression analysis may be used to achieve weighting; however, validation in independent populations is required. 27
Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events
Summary-It has recently been suggested that efficacy of the antiplatelet agent clopidogrel depends on biotransformation by the PON1 enzyme. The PON1 gene carries a common genetic variant-Q192R-which has been shown to be associated with stent thrombosis in patients treated with clopidogrel. In this latter study, carriers of the Q allele had decreased biotransformation of clopidogrel and increased cardiovascular events. In contrast to previous June 4, 2013
results, we show that the PON1 genetic variant Q192R does not influence efficacy and safety of clopidogrel in 2 large, randomized studies. In the Clopidogrel in Unstable Angina to Prevent Recurrent Events trial of clopidogrel versus placebo in non-ST-elevation-myocardial infarction (NSTEMI) patients, clopidogrel was equally effective at reducing cardiovascular events irrespective of the presence of the Q allele. Similarly, in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events of clopidogrel versus placebo in high-risk atrial fibrillation patients, no effect of the PON1 genetic variant was observed.
In conclusion, our study shows that the Q192R genetic variant does not modify the efficacy and safety of clopidogrel in NSTEMI and atrial fibrillation patients.
Conclusions-
In conclusion, our study shows that PON1 Q192R genotype does not modify the efficacy and safety of clopidogrel in patients with acute coronary syndromes. Further studies are needed to confirm or refute the association of the Q allele with adverse cardiovascular events independent of clopidogrel in secondary prevention patients. 28
Long-Term Outcomes in Hypertrophic Cardiomyopathy Caused by Mutations in the Cardiac Troponin T Gene
Summary-Ever since the first gene for hypertrophic cardiomyopathy was identified in the late 1980s, investigators have sought to link genotypes with clinical phenotypes. One of the best-known putative associations is that between mutations in the troponin T gene (TNNT2) and a high risk of sudden cardiac death. In the present study, we present the first large-scale longitudinal cohort study in patients and genotyped relatives with TNNT2 mutations. The most important finding is that despite a high prevalence of historic deaths in families, the incidence of sudden death in this prospectively managed cohort was similar to that observed in other sarcomere protein gene mutations. We also demonstrate that ventricular hypertrophy is uncommon in children and adolescents and that ventricular hypertrophy is absent in an important minority of adult patients. Together, these findings have major implications for clinical and genetic screening of families with TNNT2 mutations.
Conclusions-Left ventricular hypertrophy is rare in children with TNNT2 mutations. Left ventricular hypertrophy is absent in the minority of adults, but most have an abnormal ECG. Despite adverse family histories, the rate of cardiovascular death during follow-up was similar to that reported in large referral populations. 29
General and Disease-Specific Psychosocial Adjustment in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy With Implantable Cardioverter Defibrillators: A Large Cohort Study
Summary-Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy characterized by frequent life-threatening arrhythmias and right ventricular dysfunction. Patients are often treated with an implantable cardioverter defibrillator (ICD). Due to a younger age at ICD implant, higher proportion of female patients, and higher frequency of ICD discharge than the average patient with an ICD, as well as the inherited nature of the disease, we anticipated that our population might be at particularly high risk for difficulties adjusting to the device. Eighty-six adults with ARVD/C and an ICD completed a questionnaire measuring ICD-specific and generalized anxiety, device acceptance, and depression. Although the majority had good device acceptance and no evidence of clinically significant anxiety or depression, a significant minority had poorer adjustment. Patients with ARVD/C, particularly those who are young, had higher-than-typical levels of body image concerns and device-related distress. Anxiety levels were elevated beyond what is the norm for patients with an ICD as well. Poor device adjustment, although unfavorable in and of itself, was additionally associated with increased likelihood of clinically significant depression and anxiety. Factors associated with poor adjustment included: (1) younger age; (2) having a device implanted recently;
(3) having at least 1 ICD shock; and (4) having a poorer functional capacity. Assessment of these factors may be easily accomplished in a clinical setting. Patients with multiple risks may then be provided opportunities to discuss ICD-related concerns further. A low threshold for a mental health referral may also be appropriate.
Conclusions-Patients with ARVD/C are at elevated risk for anxiety, and young patients face challenges with device acceptance. Risk factors for poor device adjustment may be used clinically to identify patients at high-risk of psychological distress. 30
Frequent and Widespread Vascular Abnormalities in Human Signal Transducer and Activator of Transcription 3 Deficiency
Summary-STAT3 deficiency is a rare autosomal dominant primary immune deficiency in which vascular complications have been reported. We performed a systematic, prospective assessment of the entire vascular tree in 21 adult patients with STAT3 deficiency by using whole-body MRI angiography, coronary multislice computed tomography, and echo-tracking-based imaging of the carotid arteries. We found that vascular abnormalities involved arteries of all sizes and were extremely frequent and widespread, with lesions of the peripheral and brain arteries detected in more than 80% of cases and lesions of the coronary arteries seen in 50% of cases. Most of the lesions were vascular dilations (ectasia and aneurysm), and some were immediately life-threatening, as illustrated by the death of a 35-year-old patient from intracranial bleeding (caused by the rupture of a giant basilar artery aneurysm before the scheduled endovascular procedure). In accordance with these structural abnormalities, we report the occurrence of hypotrophic arterial remodeling in this population, as demonstrated by a marked decrease in the carotid intima-media thickness and a substantial increase in circumferential wall stress. Lastly, we present data from murine models showing that inhibition of STAT3-dependent signaling significantly increases the susceptibility to vascular aneurysm and fatal rupture. In conclusion, our data strongly suggest that STAT3 deficiency in humans is mechanistically linked to the vascular phenotype. We consider that patients with STAT3 deficiency should be closely monitored for their susceptibility to aneurysm formation and rupture and, accordingly, should receive appropriate preventive care.
Conclusions-Vascular abnormalities are highly prevalent in patients with STAT3 deficiency. This feature is consistent with the greater susceptibility to vascular aneurysm observed after inhibition of STAT3dependent signaling in mouse models. 31
Characterization of Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function Mutations of ANGPTL3
Summary-ANGPTL3 (angiopoietin-like protein 3), secreted by the liver and circulating in plasma, is an inhibitor of lipoprotein lipase and endothelial lipase. Lipoprotein lipase functions as a triglyceride lipase on chylomicrons and very low-density lipoprotein (VLDL); endothelial lipase functions as a phospholipase on phospholipid-rich high-density lipoprotein (HDL). In this study, we showed that complete deficiency of ANGPTL3, caused by loss-offunction mutations in the corresponding gene, was associated with low blood levels of triglycerides, low-density lipoprotein (LDL), and HDL, which resulted in the recessive condition designated familial combined hypolipidemia. Partial ANGPTL3 deficiency, as found in heterozygotes for ANGPTL3 mutations, is associated with reduced circulating levels of LDL only. We also demonstrated that serum from subjects with complete ANGPTL3 deficiency has a reduced capacity to promote in vitro cell cholesterol efflux (the first step of reverse cholesterol transport) as the result of the reduced HDL concentration. However, despite low plasma HDL levels, these subjects do not have accelerated atherosclerosis, probably because of their lifelong exposure to low blood levels of VLDL and LDL. These findings suggest that ANGPTL3 might be a target for hypolipidemic drugs. This concept is supported by the observation that ANGPTL3 deficiency reduces plasma levels of VLDL and the atherogenic alterations of blood vessels in apolipoprotein E knockout mice, an animal model of accelerated atherosclerosis. Inhibition of ANGPTL3 with small molecules, antisense oligonucleotides, or monoclonal antibodies might be protective against the accumulation of atherogenic lipoproteins by increasing the catabolism and clearance of triglyceride-rich lipoproteins.
Conclusions-Complete ANGPTL3 deficiency caused by lossof-function mutations of ANGPTL3 is associated with a recessive hypolipidemia characterized by a reduction of apolipoprotein B and apolipoprotein A-I-containing lipoproteins, changes in subclasses of high-density lipoprotein, and reduced cholesterol efflux potential of serum. Partial ANGPTL3 deficiency is associated only with a moderate reduction of low-density lipoprotein. 32
Common Genetic Variation in the 3′-BCL11B Gene Desert Is Associated With Carotid-Femoral Pulse Wave Velocity and Excess Cardiovascular Disease Risk: The AortaGen Consortium
Summary-Carotid-femoral pulse wave velocity (CFPWV) is a heritable measure of aortic stiffness that is strongly associated with increased risk for major cardiovascular disease events. However, the molecular mechanisms contributing to aortic stiffness remain largely undefined. To evaluate associations of common genetic variants with CFPWV, we conducted a meta-analysis of genome-wide association data in 9 community-based European ancestry cohorts consisting of 20 634 participants. Results were replicated in 2 additional European ancestry cohorts involving 5306 participants. We identified a highly significant locus of association at 14q32.2 in the VRK1-BCL11B gene desert in a linkage disequilibrium block that harbors 1 or more gene enhancers. We also showed that variation at this locus is associated with increased risk for major cardiovascular disease events, providing strong support for the hypothesis that increased CFPWV contributes to the pathogenesis of cardiovascular disease. We demonstrated that 2 ncRNAs as well as flanking genes, BCL11B and VRK1, are expressed in human aorta. Further work will be required to define precise mechanisms mediating the association between CFPWV and genetic variation in the VRK1-BCL11B gene desert. Elucidation of pathways affected by this locus will provide new insights into the process of aortic stiffening in humans and could yield potential targets for specific interventions that reverse or attenuate aortic stiffening and prevent the associated morbidity and mortality.
Conclusions-Common genetic variation in a locus in the BCL11B gene desert that is thought to harbor 1 or more gene enhancers is associated with higher CFPWV and increased risk for cardiovascular disease. Elucidation of the role this novel locus plays in aortic stiffness may facilitate development of therapeutic interventions that limit aortic stiffening and related cardiovascular disease events. 33
A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes
Summary-Torsades de pointes during drug administration has been recognized for decades. With the use of QT-prolonging antiarrhythmic drugs, the incidence is 1% to 5%, whereas the problem appears to be much more rare with "noncardiovascular" therapies, such as pentamidine, methadone, or haloperidol. Many of the clinical features phenocopy the congenital long-QT syndrome, suggesting the hypothesis-tested in the present study-that variants in genes encoding cardiac ion channels or their modifiers might modulate risk. The present study analyzed common variation in a set of these genes and identified a single-nucleotide polymorphism, resulting in D85N in the potassium channel-modifying protein KCNE1 as a risk factor. Although the genetic result only establishes an association, studies of D85N function strongly suggest it is in fact the causative risk variant. D85N frequency is 1.8 to 2.9% in control populations, and the risk conferred by the variant is quite high, with an odds ratio of 9.0. These data raise the question of whether all patients prescribed QTprolonging drugs, or at least those exposed to QT-prolonging antiarrhythmics, should be tested before drug prescribing. This appears to be a cumbersome undertaking in the context of current clinical practice. A future perspective is to embed genomic information into electronic medical record systems and to use the information when needed, for example, when a drug is prescribed. As more and more variants associated with unusual phenotypes are identified and inexpensive large-scale genotyping comes on line for clinical applications, the idea of preemptive genotyping in this fashion will become increasingly appealing.
Conclusions-This high-density candidate SNP approach identified a key potassium channel susceptibility allele that may be associated with the rare adverse drug reaction torsades de pointes. 34
Cardiac Defects Are Infrequent Findings in Individuals With 8p23.1 Genomic Duplications Containing GATA4
Summary-The GATA4 gene is critical to regulating myocardial differentiation and function. Haploinsufficiency of GATA4 is strongly associated with conotruncal and septal heart defects. However, it is inconclusive whether duplicated GATA4 may cause congenital heart defects (CHD). This study reports on 8 probands and 2 relatives with pathogenic genomic imbalances containing GATA4 through evaluation of 1645 consecutive pediatric patients with various developmental disorders by microarray-based comparative genomic hybridization. Four probands contain an ≈4.0-Mb interstitial duplication of 8p23.1 flanked by the 2 olfactory receptor gene clusters. None of the 4 patients has CHD or any other heart diseases, whereas 1 mother who transmitted the duplication to her child has a history of aortic stenosis. Two patients who carried multiple genomic abnormalities, including a duplication containing GATA4, have complex CHD. Only 1 of the 3 individuals carrying genomic deletion containing GATA4 has atrial and ventricular septal defects. Based on these findings, we have made the following conclusions: e656 Circulation June 4, 2013 (1) Cardiac defects are infrequent findings in individuals with 8p23.1 genomic duplications containing GATA4; (2) a 0.24% detection rate of this duplication in this study is significantly higher than previously estimated; (3) observation in the patients with multiple genomic abnormalities and complex CHD is consistent with a 2-hit model emphasizing accumulative effects of >1 insult to the genome, leading to a visible or more severe clinical manifestation; and (4) haploinsufficient GATA4 may show variable expressivity with a wide spectrum of clinical findings, including CHD.
Conclusions-Cardiac defects are infrequent findings in individuals with 8p23.1 genomic duplications containing GATA4. A 0.24% detection rate of this duplication in this study is significantly higher than previously estimated. Observation in 2 patients with multiple genomic abnormalities and complex CHD is consistent with a 2-hit model that emphasizes accumulative effects of >1 insult to the genome, leading to a visible or more severe clinical manifestation. Haploinsufficient GATA4 may show variable expressivity with a wide spectrum of clinical findings, including CHD. 35 
